Cargando…

The Prognostic Role of Plasma Epstein-Barr Virus DNA Levels in the Middle of Intensity Modulated Radiation Therapy to Guide Cisplatin Dose Recommendation in Concurrent Chemoradiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma: A Large Cohort Study

PURPOSE: Our purpose was to investigate the prognostic role of plasma Epstein-Barr virus (EBV) DNA levels in the middle of intensity modulated radiation therapy (IMRT). METHODS AND MATERIALS: In total, 1881 patients with stage III-IVa tumors were included. The overall survival (OS) and progression-f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zhen-Chong, Du, Chao-Chao, Liu, Li-Ting, Liang, Yu-Jing, Tang, Lin-Quan, Chen, Qiu-Yan, Mai, Hai-Qiang, Guo, Shan-Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Scientific Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133362/ https://www.ncbi.nlm.nih.gov/pubmed/35647403 http://dx.doi.org/10.1016/j.adro.2022.100908

Ejemplares similares

Prognostic Value of Plasma Epstein–Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Chen, Wen-Hui, et al.
Publicado: (2016)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study
por: Guo, Shan-Shan, et al.
Publicado: (2016)

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein–Barr virus DNA level after induction chemotherapy
por: Liu, Sai-Lan, et al.
Publicado: (2020)

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
por: Li, You Quan, et al.
Publicado: (2018)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

Individualized concurrent chemotherapy by pretreatment plasma Epstein‐Barr viral DNA in II‐III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort
por: Sun, Xue‐Song, et al.
Publicado: (2019)

The Criteria to Confirm the Role of Epstein-Barr Virus in Nasopharyngeal Carcinoma Initiation
por: Gu, Ai-Di, et al.
Publicado: (2012)

Roles of Inflammasomes in Epstein–Barr Virus-Associated Nasopharyngeal Cancer
por: Looi, Chin King, et al.
Publicado: (2021)

Quality-Adjusted Life Years and Disability-Adjusted Life Years Are Better With Concurrent Chemoradiation Therapy Than Induction Chemotherapy Followed by Chemoradiation Therapy in Nasopharyngeal Carcinoma
por: Nittala, Mary R, et al.
Publicado: (2021)

Different Prognostic Values of Plasma Epstein-Barr Virus DNA and Maximal Standardized Uptake Value of (18)F-FDG PET/CT for Nasopharyngeal Carcinoma Patients with Recurrence
por: Shen, Ting, et al.
Publicado: (2015)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

The role of Epstein–Barr virus in nasopharyngeal carcinoma
por: Su, Zhi Yi, et al.
Publicado: (2023)

The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study
por: Liu, Sai-Lan, et al.
Publicado: (2019)

Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma
por: Renaud, Sarah, et al.
Publicado: (2020)

Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein–Barr virus DNA level
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Recommendations for Epstein-Barr virus–based screening for nasopharyngeal cancer in high- and intermediate-risk regions
por: Lam, W K Jacky, et al.
Publicado: (2023)

Spotted Temporal Lobe Necrosis following Concurrent Chemoradiation Therapy Using Image-Guided Radiotherapy for Nasopharyngeal Carcinoma
por: Chiang, Yu-Wei, et al.
Publicado: (2022)

Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma
por: Zhang, Hui, et al.
Publicado: (2017)

Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer
por: Kong, Tae Wook, et al.
Publicado: (2012)

Influence of Caregiver Presence During Physician Office Visits on Patients Undergoing Chemoradiation Therapy for Esophageal Cancer
por: Ho, Joseph K., et al.
Publicado: (2021)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study
por: Chen, Qiu-Yan, et al.
Publicado: (2018)

The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
por: Wang, Zhi-Qiang, et al.
Publicado: (2022)

Response to the hunt for the perfect biomarker in nasopharyngeal carcinoma—the RRAS “race” beyond Epstein-barr virus?
por: Xiao, Ruowen, et al.
Publicado: (2019)

Impact of Neoadjuvant Chemotherapy on the Administration of Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma
por: Maas, Benjamin, et al.
Publicado: (2018)

Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells
por: Tsang, Chi Man, et al.
Publicado: (2014)

Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis
por: Richardo, Timmy, et al.
Publicado: (2020)

Nasopharyngeal Carcinoma: The Role of the EGFR in Epstein–Barr Virus Infection
por: Peng, Xintong, et al.
Publicado: (2021)

Sequence analysis of the Epstein-Barr virus (EBV) BRLF1 gene in nasopharyngeal and gastric carcinomas
por: Jia, Yuping, et al.
Publicado: (2010)

Achalasia Combined with Esophageal Cancer Treated by Concurrent Chemoradiation Therapy
por: Park, Jun Chul, et al.
Publicado: (2009)

Epstein-Barr Virus (Infectious Disease and Therapy)
por: Pagano, Joseph
Publicado: (2006)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy
por: Guo, Shan-Shan, et al.
Publicado: (2015)

Targeting Epstein–Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy
por: Xiao, L, et al.
Publicado: (2014)

Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study
por: Chen, Qiu-Yan, et al.
Publicado: (2018)

Epstein-Barr virus in nasopharyngeal and salivary gland carcinomas of Greenland Eskimoes.
por: Saemundsen, A. K., et al.
Publicado: (1982)

Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma
por: Hutajulu, Susanna Hilda, et al.
Publicado: (2014)

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
por: Chan, K.C. Allen
Publicado: (2014)

Identification of genes involved in Epstein-Barr virus-associated nasopharyngeal carcinoma
por: Wang, Junguo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nlijb28m29acoecgj7f3u6pb99